Over 50 combined years of medical practice and product innovation

Evan C. Unger, MD, FACR

Chief Executive Officer

Evan Unger M.D. is a renowned expert on ultrasound contrast media. He founded MVT to advance the field of ultrasound contrast agents and theranostics. Dr. Unger has also founded three other biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs, including Definity®, the world’s #1 selling ultrasound contrast agent. ImaRx Pharmaceutical was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using ultrasound and microbubbles to treat ischemic stroke. Dr. Unger co-founded NuvOx, a clinical-stage biotech company that is in Phase II trials for stroke and brain cancer. He is a co-inventor on the issued U.S. patent covering MVT-100 and also an inventor on over 120 other issued US patents. He is a board-certified radiologist and has had an appointment as a Professor of Radiology and Biomedical Engineering at the University of Arizona and serves as President and CEO of NuvOx Pharma. 

Emmanuelle J. Meuillet, PhD

VP Research & Development

Emmanuelle J. Meuillet is an accomplished scientist, inventor and entrepreneur focusing on drug discovery and development.  Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France).  She has had an appointment as an Associate Professor at the University of Arizona.  Over the years, Dr. Meuillet has managed many NIH funded programs in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects.  She founded two biotech companies, PHusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules.  Dr. Meuillet is a consultant for the NIH and DoD. She is the author of more than fifty peer reviewed manuscripts and reviews, she is an inventor on five patents and she belong to several editorial boards for specialized cancer journals. She joined Microvascular Therapeutics in 2018. 

Wyatt Unger, MD, MBA

Chief Medical Officer

Dr. Unger received his B.A. in economics from Northwestern University, M.D. from the University of Arizona College of Medicine with Alpha Omega Alpha honors, and MBA from the University of Arizona Eller College of Business.  Dr. Unger completed diagnostic radiology residency training at Arizona, where he also completed a fellowship in Abdominal MRI imaging. Dr. Unger has authored multiple peer-reviewed abstracts and journal publications, worked as a consultant in clinical development and clinical trial design for Nuvox Pharmaceutical and serves as the Chief Medical Officer for Microvascular Therapeutics where he is overseeing clinical development and clinical trial design for their pharmaceutical candidate MVT-100.

Wyatt Unger, MD, MBA

Chief Medical Officer

Dr. Unger received his B.A. in economics from Northwestern University, M.D. from the University of Arizona College of Medicine with Alpha Omega Alpha honors, and MBA from the University of Arizona Eller College of Business.  Dr. Unger completed diagnostic radiology residency training at Arizona, where he also completed a fellowship in Abdominal MRI imaging. Dr. Unger has authored multiple peer-reviewed abstracts and journal publications, worked as a consultant in clinical development and clinical trial design for Nuvox Pharmaceutical and serves as the Chief Medical Officer for Microvascular Therapeutics where he is overseeing clinical development and clinical trial design for their pharmaceutical candidate MVT-100.

© 2020 Microvascular Therapeutics, LCC. All rights reserved.

1635 East 18th Street  •  Tucson, Arizona 85719  •  (520) 624-6688

*Definity is a registered trademark of Lantheus

  • LinkedIn